

# ASENT

## 17th Annual Meeting

February 19 – 21, 2015

Georgetown University Hotel and Conference Center  
3800 Reservoir Road, NW  
Washington, DC

### Vision Statement

To advance the science of neurotherapeutics and  
to improve and accelerate the development  
of new treatments.

## PROGRAM BOOK



[asent.org](http://asent.org)

### Schedule-At-A-Glance

#### Thursday, February 19, 2015

8:15 a.m. – 4:30 p.m.  
Fairmont Hotel  
Fairmont Ballroom  
Joint Scientific Educational Session with ISCTM

5:00 p.m. – 7:30 p.m.  
Business Center, West Lobby

Registration

6:00 p.m. – 7:30 p.m.  
Grand Ballroom - Salon H

Welcome Reception

#### Friday, February 20, 2015

7:30 a.m. – 8:30 a.m.

Continental Breakfast

7:30 a.m. – 6:30 p.m.  
Business Center, West Lobby

Registration

8:00 a.m. – 12:30 p.m.  
Grand Ballroom - Salons A/B

General Session – Neuroinflammation

12:30 p.m. – 1:25 p.m.  
Grand Ballroom – Salon H

Special Interest Topics Networking Luncheon  
(Ticket required)

1:30 p.m. – 5:30 p.m.  
Grand Ballroom - Salons A/B

Pipeline Session

5:30 p.m. – 7:15 p.m.  
Grand Ballroom – Salon H

Networking Reception, Information Exchange  
and Poster Presentation

7:30 p.m. – 9:00 p.m.  
Grand Ballroom – Salon H

Dinner Symposium:  
Current Status and Future Opportunities  
in Generic Drugs (Ticket required)

#### SATURDAY, FEBRUARY 21, 2015

8:00 a.m. – 4:30 p.m.  
Business Center, West Lobby

Registration

8:30 a.m. – 9:00 a.m.  
Grand Ballroom - Salons A/B

Annual Business Meeting

8:45 a.m. – 9:45 a.m.

Continental Breakfast


9:00 a.m. – 1:50 a.m.  
Grand Ballroom - Salons A/B

General Session:  
What's New in Orphan Drug Development?

12:00 p.m. – 4:30 p.m.  
Grand Ballroom - Salons A/B

Lifestyle as Neurotherapeutics  
(Ticket required)

All events take place at the Georgetown University Hotel & Conference Center  
unless otherwise noted.



ASENT

342 North Main Street, Suite 301  
West Hartford, CT 06117-2507  
Phone: 860-586-7570 | Fax: 860-586-7550  
Email: [info@asent.org](mailto:info@asent.org) | [www.asent.org](http://www.asent.org)

# ASENT Corporate Partners

List as of February 13, 2015

**Gold**  
**\$10,000 - \$24,999**

**Biogen Idec, Inc.**

**Silver**  
**\$5,000 - \$9,999**

**Bracket Global  
Lundbeck, Inc.**

**Bronze**  
**\$2,500 - \$4,999**

**Adamas Pharmaceuticals, Inc.**  
**Cognitive Research Corporation**  
**inVentiv Health Clinical**  
**KM Pharmaceuticals Consulting, LLC**  
**Sughrue Mion PLLC**

**Supporter**  
**\$1,000 - \$2,499**

**Chase Pharmaceuticals Corporation**  
**NeuroPace, Inc.**  
**Riverside Pharmaceutical Corporation**  
**Westhaven Pharmaceuticals**

**asent.org**

# American Society for Experimental NeuroTherapeutics

## ASENT 2014 - 2015 Board of Directors

### OFFICERS

#### PRESIDENT

**Howard Federoff, MD, PhD**  
Georgetown University

#### PRESIDENT-ELECT

**Martha Morrell, MD**  
NeuroPace, Inc.

#### IMMEDIATE PAST PRESIDENT

**Michael Rogawski, MD, PhD**  
University of California, Davis

#### SECRETARY

**Jesse Cedarbaum, MD**  
Biogen Idec, Inc.

#### TREASURER

**Robin Elliott, MA**  
Parkinson's Disease Foundation &  
World Parkinson Congress

#### DIRECTORS 2012-2015

**Steven DeKosky, MD**  
University of Virginia School of  
Medicine

#### Robert Griggs, MD

University of Rochester School of  
Medicine & Dentistry

#### Philip Perera, MD, MBA

Dart NeuroScience LLC

#### DIRECTORS 2013-2016

**Timothy Coetzee, PhD**  
National Multiple Sclerosis Society

#### Joseph Hulihan, MD

Janssen Global Services

**Lynn Kramer, MD**  
Eisai, Inc.

**Bernard Ravina, MD**  
Voyager Therapeutics, Inc.

#### DIRECTORS 2014-2017

**Merit Cudkowicz, MD, MSc**  
Massachusetts General Hospital

#### Russell Katz, MD

**Victor Krauthamer, PhD**  
FDA Office of Device Evaluation

#### Richard Rudick, MD

Biogen Idec, Inc.

#### EX-OFFICIO

#### DEVELOPMENT COMMITTEE CHAIR

**Kathleen Clarence-Smith, MD, PhD**  
KM Pharmaceutical Consulting, LLC

#### NEUROTHERAPEUTICS® EDITOR-IN-CHIEF

**M. Maral Mouradian, MD**  
Rutgers University

#### PROGRAM COMMITTEE CO-CHAIRS

**Bennett Lavenstein, MD**  
Children's Hospital Medical Center

#### MARTHA MORRELL, MD

NeuroPace, Inc.

#### NIH BLUEPRINT COURSE LIAISON

**Barbara Slusher, PhD, MAS**  
Johns Hopkins School of Medicine

#### FEDERAL LIAISON

**Rajesh Ranganathan, PhD**  
NIH/NINDS

**17th Annual Meeting  
Program Committee**

**Bennett L. Lavenstein, MD, Co-Chair**  
Children's Hospital Medical Center

**Martha Morrell, MD, Co-Chair**  
NeuroPace, Inc.

**C. Anthony Altar, PhD,**  
AssureRx Health, Inc.

**Mitchell Brin, MD**  
Allergan, Inc.

**Amy Chappell, MD**

**Kathleen E. Clarence-Smith, MD, PhD**  
KM Pharmaceutical Consulting, LLC

**Robin A. Elliott, MA**  
Parkinson's Disease Foundation &  
World Parkinson Congress

**Howard Federoff, MD, PhD**  
Georgetown University Medical  
Center

**Jacqueline A. French, MD**  
New York University Comprehensive  
Epilepsy Center

**Mark Forrest Gordon, MD**  
Boehringer-Ingelheim

**Robert W. Hamill, MD**  
University of Vermont College of  
Medicine

**Cynthia L. Harden, MD**  
Long Island Jewish Medical Center

**Petra Kaufmann, MD, MSc**  
NINDS/NIH

**Stella Papa, MD**  
Emory University

**Roger J. Porter, MD**

**Richard Ransohoff, MD**  
Biogen, Idec.

**Marc Walton, MD, PhD**  
Janssen Research Foundation

**Table of Contents**

Meeting Room Layout ..... 2

Program Schedule ..... 3-7

Annual Business Meeting ..... 8

Meeting Evaluation/How Do I Obtain CME Credits? ..... 9

Continuing Medical Education Information..... 10-12

17th Annual Meeting Program Committee..... 16

ASENT Board of Directors ..... 17

Schedule-At-A-Glance.....Back Cover





American Society for  
Experimental NeuroTherapeutics

Program Schedule (Continued)

**FRIDAY, FEBRUARY 20, 2015**

10:45 a.m. – 11:25 a.m.  
**Regulation of Immune Responses in  
Paraneoplastic Neurologic Disorders**

Nathalie Blachère, PhD  
Rockefeller University

11:25 a.m. – 12:05 p.m. **B cells as Therapeutic Targets in Multiple Sclerosis**

Amit Bar-Or, MD, FRCPC  
Montreal Neurological Institute and Hospital

12:05 p.m. – 12:30 p.m. **Panel Discussion**

12:30 p.m. – 1:25 p.m.  
**Special Interest Topics  
Networking Luncheon**  
*Grand Ballroom - Salon H*

1:30 p.m. – 5:30 p.m.  
**Pipeline Session**  
*Grand Ballroom - Salon A/B*

Co-chairs: Kathleen Clarence-Smith, MD, PhD; Roger Porter, MD;  
Rajesh Ranganathan, PhD, NINDS

The latest projects in Neurology ready for translation and seeking support to  
increase their chances for success and to get treatment to patients sooner.

1:30 p.m. – 3:20 p.m. **Oral Presentations**

3:20 p.m. – 3:40 p.m. **Break**

3:40 p.m. – 5:30 p.m. **Oral Presentations (Continued)**

5:30 p.m. – 7:15 p.m.  
**Networking Reception, Information  
Exchange and Poster Presentation**  
*Grand Ballroom - Salon H*

American Society for  
Experimental NeuroTherapeutics

Notes

**American Society for  
Experimental NeuroTherapeutics**

**Continuing Medical Education  
Statement and Session Objectives**  
(Continued)

- Mark Gordon, MD\*\*  
Boehringer Ingelheim Pharmaceuticals, Inc., employee
- Martha Morrell, MD\*\*  
NeuroPace, Inc., employee
- Roger Porter, MD\*\*  
AurimMed, stockholder
- Richard Ransohoff, MD\*\*  
Biogen Idec, Inc., employee
- Raymond W. Urbanski, MD, PhD  
Mylan, Inc., served as Chief Medical Officer
- Marc Walton, MD, PhD\*\*  
Janssen Research and Development, employee

**American Society for  
Experimental NeuroTherapeutics**

**Program Schedule** (Continued)  
**FRIDAY, FEBRUARY 20, 2015**

**7:30 p.m. – 9:00 p.m.**  
**Grand Ballroom - Salon A/B**  
**Dinner Symposium – Current Status  
and Future Opportunities in  
Generic Drugs: Industry, Investigator,  
and Regulatory Perspectives**

**Program**

Co-chairs: Mitchell Brin, MD, Allergan, Inc.; Kathleen Clarence-Smith, MD, PhD,  
KM Pharmaceutical Consulting, LLC; Marc Walton, MD, PhD, Janssen Research  
Foundation

7:30 p.m. – 8:15 p.m.

**Dinner**

8:15 p.m. – 8:25 p.m.

**Overview of Generic Drugs**

Ray Urbanski, MD, PhD  
LNR BioPharma Consulting, LLC

8:25 p.m. – 8:35 p.m.

**Issues with Generic Antiepileptic Drugs**

William Theodore, MD  
NIH

8:35 p.m. – 8:45 p.m.

**FDA Regulatory Science Interests and  
Generic Drugs**

Larissa Lapteva, MD  
FDA

8:45 p.m. – 9:00 p.m.

**Panel Discussion**

**Program Schedule** (Continued)

**SATURDAY, FEBRUARY 21, 2015**

**ASENT Annual Business Meeting**

**8:30 a.m. – 9:00 a.m.**  
*Grand Ballroom - Salon A/B*

**9:00 a.m. – 11:50 a.m.**  
*Grand Ballroom - Salon A/B*

**Program**

Chair: Petra Kaufmann, MD, MSc, NIH/NCATS

9:00 a.m. – 9:05 a.m.

**Opening Remarks**  
Petra Kaufmann, MD, MSc, NIH/NCATS

9:05 a.m. – 9:20 a.m.

**Review of Rare Disease Drug Development:  
FDA Perspectives**  
Andrew Mulberg, MD, FAAP, CPI  
FDA

9:20 a.m. – 9:30 a.m.

**The Role of the Patient & Advocate in Public-Private  
Partnerships to Advance Orphan Drug Development**  
Ronald Bartek  
Friedrich's Ataxia Research Alliance

9:30 a.m. – 9:40 a.m.

**From the Doctor's Office to Drug Development:  
a Clinician-researcher Perspective to Orphan  
Drug Development**  
Jinsy Andrews, MD  
Cytokinetics

9:40 a.m. – 9:50 a.m.

**An Industry Perspective on Orphan Drug  
Development**  
Bernard Ravina, MD, MS  
Voyager Therapeutics, Inc.

9:50 a.m. – 10:00 a.m.

**Exploring Global Opportunities in Rare Diseases**  
Cristina Csimma, PharmD, MHP  
Csimma, LLC

10:00 a.m. – 10:10 a.m.

**Orphan Drug Development, NCATS Perspective**  
Petra Kaufmann, MD, MSc, NIH/NCATS

10:10 a.m. – 10:30 a.m.

**Break**

10:30 a.m. – 11:50 a.m.

**Panel Discussion featuring:**

- Increased recent orphan drug activities and the lessons learned
- Importance of multiple stakeholder collaboration and models that work
- Public-Private partnerships that advance orphan drug development
- How do we approach an increasing number of companies in a rare disease space when the population of targeted patients is small?
- What innovations could be realized that would accelerate orphan drug development?

**Continuing Medical Education  
Statement and Session Objectives**  
(Continued)

**Interests to Disclose/COI/Bias Resolved**

C. Anthony Altar, PhD\*\*  
AssureRx Health, Inc., employee

Jinsy Andrews, MD, MSc  
Cytokinetics, Inc., employee

Mitchell Brin, MD\*\*  
Allergan, employee

Kathleen Clarence-Smith, MD, PhD\*\*  
KM Pharmaceutical Consulting, LLC; Chase Pharmaceuticals, Inc.;  
Westhaven Pharmaceuticals; Riverside Pharmaceuticals;  
CSK Consulting, owner/partner of all

Cristina Csimma, PharmD, MHP  
Columbia Labs, Vtesse, Inc., Board of Directors,  
Akashi, Business Advisory Board

Howard J. Federoff, MD, PhD\*\*  
MedaGenesis Therapeutix, founder and consultant;  
Socratech, founder; Ovid Therapeutics, consultant

Jacqueline French, MD\*\*  
Jacqueline French is President of the Epilepsy Study Consortium.  
All consulting is done on behalf of the consortium, and fees are paid to the consortium. The NYU Comprehensive Epilepsy Center receives salary support from the consortium; JF has acted as a consultant for Acorda, Biotie, Brabant Pharma, Eisai Medical Research, Glaxo Smith-Kline, GW Pharma, Impax, Johnson and Johnson, Marathon Pharmaceuticals, Marinus, Neusentis, Novartis, Pfizer, Sage, Sunovion, SK life sciences, Supernus Pharmaceuticals, Takeda, UCB, Upsher-Smith, Ultragenyx, Vertex, Zynerva, grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK life sciences, UCB, Upsher-Smith, Vertex, grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium; She is on the editorial board of Lancet Neurology, Neurology Today and Epileptic disorders, and is an associate editor of Epilepsia.



## Continuing Medical Education Statement and Session Objectives

Session Objectives: At the completion of the meeting, participants will be able to:

- Understand the various pre-morbid inflammatory aspects of progressive neurodegenerative disease.
- Obtain and order those tests that will precisely influence patient outcomes through therapy.

Meeting Disclaimer: Regarding materials and information received, written or otherwise, during this activity: The scientific views, statements and recommendations expressed during this CME activity represent those of the authors and speakers, and do not necessarily represent the views of the University of Vermont.

Interest Disclosures: As an organization accredited by the ACCME to sponsor continuing medical education activities, The University of Vermont is required to disclose any real or apparent conflicts of interest (COI) that any speakers may have related to the content of their presentations.

The University of Vermont requires that each speaker participating in a program designated for AMA Physician's Recognition Award Category 1 credit disclose any financial interest/arrangement or affiliation with a corporate organization that may impact on his/her presentation (i.e. grants, research support, honoraria, member of speakers' bureau, consultant, major stock shareholder, etc.)

### No Interests to Disclose:

Amit Bar-Or, MD, FRCPC  
Ronald Bartek  
M. Flint Beal, MD  
Nathalie Blachère, PhD  
Amy Chappell, MD\*\*  
Robin Elliott, MA\*\*  
Kirk Erickson, PhD  
Nicole M. Gatto, MPH, PhD  
Robert W. Hamill, MD\*\*  
Petra Kaufmann, MD, MSc\*\*  
Larissa Lapteva, MD

Bennett Lavenstein, MD\*\*  
Martha Claire Morris, ScD  
Andrew E. Mulberg, MD, FAAP, CPI  
Stella M. Papa, MD\*\*  
Giselle Petzinger, MD  
Rajesh Ranganathan, PhD  
Bernard Ravina, MD, MS  
Dorothy Schafer, PhD  
William H. Theodore, MD  
Angela Vincent, MBBS (Hon PhD  
Bergen), FRCPath, FMedSci, FRS

## Program Schedule (Continued)

**SATURDAY, FEBRUARY 21, 2015**

**12:00 p.m. – 4:30 p.m.**  
**Lifestyle as Neurotherapeutics**  
**(Lunch - ticket required)**  
*Grand Ballroom - Salon A/B*

### Program:

Co-chairs: Amy Chappell, MD; Robert Hamill, MD, University of Vermont

12:00 p.m.

### Lunch

12:35 p.m. – 12:40 p.m.

**Opening Remarks**  
Robert Hamill, MD  
University of Vermont

12:40 p.m. – 1:00 p.m.

**What is Lifestyle Medicine?**  
Amy Chappell, MD

1:00 p.m. – 1:30 p.m.

**Research from the Adventist Health Study-2 and  
Neuroepidemiological Investigations**  
Nicole M. Gatto, MPH, PhD  
Loma Linda University School of Public Health

1:30 p.m. – 2:00 p.m.

**Effects of Exercise and Nutrition on Brain  
Mitochondria and Synapses in  
Neurodegenerative Diseases**  
M. Flint Beal, MD  
Weill Medical College of Cornell University

2:00 p.m. – 2:30 p.m.

**Nutrition and the Aging Brain**  
Martha Claire Morris, ScD  
Rush University

2:30 p.m. – 2:45 p.m.

### Break

2:45 p.m. – 3:15 p.m.

**Aging, Exercise, and Brain Plasticity**  
Kirk Erickson, PhD  
University of Pittsburgh

3:15 p.m. – 3:45 p.m.

**Exercise as a Neurotherapeutic in  
Parkinson's Disease**  
Giselle Petzinger, MD  
University of Southern California

3:45 p.m. – 4:30 p.m.

### Panel Discussion


4:30 p.m.

**Close Annual Meeting**  
Howard Federoff, MD, PhD  
Georgetown University Medical Center

## **Annual Business Meeting**

**Saturday, February 21, 2015**  
**Georgetown University**  
**Hotel & Conference Center**  
*Grand Ballroom - Salon A/B*  
**8:30 a.m. – 9:00 a.m.**

- I. Call to Order
- II. Financial Report
- III. *Neurotherapeutics*<sup>®</sup> Journal Report
- IV. Membership Report
- V. Old Business
- VI. New Business
- VII. Adjournment



## **Meeting Evaluation/ How Do I Obtain CME Credits?**

To obtain a CME certificate for the ASENT 17th Annual Meeting, please access the online evaluation on our website [www.asent.org](http://www.asent.org). A link to the evaluation is on the homepage. Evaluations must be completed by **Monday, March 23, 2015**, in order to receive credit.

ASENT's 17th Annual Meeting has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Vermont and the American Society for Experimental NeuroTherapeutics. The University of Vermont College of Medicine (UVM) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Vermont designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.